Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA401 dose-ranging trial in post-herpetic neuralgia
2016-000280-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olodanrigan in postherpetic neuralgia (PHN) (4 arms), sponsored by Novartis. Primary endpoint: Dose-response in change in weekly mean 24-hour average pain score. Started Mar 2017; status: completed.
02
Drugs
olodanrigan
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2016-000280-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000280-16.